For the full year 2025, Tenon Medical achieved record revenue of $3.9 million, a 20% increase from $3.3 million in 2024. The gross profit for the year also saw a substantial rise, reaching $2.4 million, which is a 38% increase compared to the previous year. The gross margin improved to 60%, up from 52% in 2024, reflecting the company's operational efficiency and effective cost management.
In addition to the impressive financial metrics, Tenon Medical secured FDA 510(k) clearance for its next-generation SImmetry®+ SI Joint Fusion System, which is expected to broaden its market reach and enhance its product offerings. The company has also successfully completed initial procedures with the new system at Centers of Excellence, which is crucial for advancing its commercial rollout and gaining surgeon adoption.
The company hosted a conference call on the same day to discuss these results and provide further insights into its strategic initiatives and future outlook. CEO Steven M. Foster expressed optimism about the company’s trajectory, highlighting the strong momentum in adoption and the potential for sustainable growth moving forward. He noted that the company is well-positioned to capitalize on its differentiated portfolio and increasing surgeon engagement, which will drive value for patients and shareholders alike.
Overall, Tenon Medical's strong performance in Q4 2025 and the full year reflects its commitment to innovation and operational excellence in the medical device sector, particularly in addressing sacro-pelvic disorders.
